Articles tagged with: Patients

Genomics project reaches goal of 100,000 genomes sequenced from NHS patients

Posted in General News Published by Administrator 06 December 2018

Genomics project reaches goal of 100,000 genomes sequenced from NHS patients

UK Health Secretary Matt Hancock announced yesterday that a project involving Queen Mary University of London researchers has reached its goal of sequencing 100,000 whole genomes from NHS patients. The 100,000 Genomes Project, led by Genomics England in partnership with NHS England, is a ground-breaking programme which has been based at Queen Mary’s Charterhouse Square campus since 2013, involving 24 of its staff members.

Tackling the deadliest cancer type

Posted in General News Published by Bethan Warman 30 November 2018

Our lung cancer research

Tackling the deadliest cancer type

This month is Lung Cancer Awareness Month. Lung cancer is the third most common cancer in the UK, with 46,700 new cases diagnosed each year. Approximately 35,600 people lose their lives annually as a result of lung cancer in the UK, making it the most common cause of cancer-related mortality. Only 5% of those affected survive their cancer for 10 years or more in the UK, and this survival rate has not shown much improvement over the last four decades.

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

Posted in General News, BCI on the Road, Publications Published by Bethan Warman 22 October 2018

New phase 3 clinical trial using combination therapy extends survival in triple-negative breast cancer

New research led by Barts Cancer Institute and St Bartholomew’s Hospital has provided new hope for people with an aggressive type of breast cancer. The phase 3 clinical trial has shown that by using a combination of immunotherapy and chemotherapy, the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Posted in General News, Publications Published by Bethan Warman 17 October 2018

Immunotherapy shows promise for patients with metastatic triple-negative breast cancer

Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC). The phase 1 clinical trial, led by Prof Peter Schmid, Centre Lead for BCI’s Centre for Experimental Cancer Medicine, is the first to report the long-term safety and efficacy of the drug for mTNBC, and may represent significant steps forward for treatment of this disease.

Blood Cancer Awareness Month 2018

Posted in General News Published by Bethan Warman 28 September 2018

Blood Cancer Awareness Month 2018

Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year. The three main blood cancer types are leukaemia, lymphoma and myeloma; however, there are over 100 individual types.

World Cancer Research Day 2018

Posted in General News Published by Bethan Warman 24 September 2018

World Cancer Research Day 2018

Today is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive. To continue to improve these statistics, it is vital to identify new and more effective early detection methods and treatments that can improve the lives of those with cancer.

VOICE 2018: From bedside to bench

Posted in General News, Engagement Published by Bethan Warman 12 September 2018

VOICE 2018: From bedside to bench

Last week, BCI held the 2018 VOICE (Vision On Information, Confidence & Engagement) course- a study week that aims to take patient advocates from bedside to bench by providing an introduction to basic cancer biology, research terminology and study design. This unique course was developed by Independent Cancer Patients’ Voice (ICPV)- a patient advocate group led by patients for patients- to empower patient advocates and increase their confidence to get involved in the cancer conversation.

Pancreatic Cancer UK Grand Challenge

Posted in General News, Grants & Awards Published by Bethan Warman 27 July 2018

PCUK’s largest ever research fund

Pancreatic Cancer UK Grand Challenge

Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be used for the development of a type of immunotherapy, known as CAR-T cell therapy, to treat pancreatic cancer.

Immunotherapy harnesses the body’s own immune system to identify and kill cancer cells, and has been demonstrated to be an effective treatment option in a variety of cancer types. In CAR-T cell therapy, T cells- key immune cells responsible for fighting infected cells- are isolated from patient blood samples, modified outside of the body and reinjected back into the patient. Once back in the body, the T cells are equipped to target and attack tumours.

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Posted in General News, Conferences, BCI on the Road Published by Bethan Warman 15 June 2018

BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials

Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. The Centre Lead of our Centre for Experimental Cancer Medicine (CECM), Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles of the CECM and Director of the Barts Cancer Centre, presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.

Research suggests improved detection rates are needed to maximise cancer prevention

Posted in General News, Publications Published by Bethan Warman 08 June 2018

Research suggests improved detection rates are needed to maximise cancer prevention

Current detection strategies are found to have identified only 2.6% of the BRCA gene mutation carriers in the Greater London population, according to a recent study published in the Journal of Medical genetics. The findings of the study, performed by researchers from the BCI’s Centre for Experimental Cancer Medicine, led by Dr Ranjit Manchanda, suggest that enhanced and new approaches are required to maximise the opportunity for breast and ovarian cancer prevention.

BRCA1 and BRCA2 mutations are associated with an increased risk of breast and ovarian cancer. A recent study has shown that about 72 and 69% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop breast cancer by 80 years of age. Additionally, 44 and 17% of women who inherit a harmful mutation in the BRCA1 and BRCA2 genes, respectively, develop ovarian cancer by 80 years of age. Identifying mutation carriers is therefore critical to reduce the number of BRCA-associated cancers.

[12  >>  
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.